Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 14/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 11/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.51 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | PRKACA | P17612 | 2/20 | 0.40 |
| ▸ | PRKACG | P22612 | 2/20 | 0.40 |
| ▸ | PRKACB | P22694 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16205500 | 0.84 | CLK1 (0.51) | CLK1CDK5CDK5R1MAP3K14CCNB2 | |
| SCHEMBL16205552 | 0.84 | MAP3K14 (0.64) | CLK1CDK5CDK5R1MAP3K14PDK1 | |
| SCHEMBL16205586 | 0.84 | RPS6KA5 (0.39) | CLK1CDK5CDK5R1MAP3K14PDK1 | |
| SCHEMBL16205354 | 0.84 | CLK1 (0.48) | CLK1CDK5CDK5R1MAP3K14CCNB2 | |
| SCHEMBL1612715 | 0.83 | CLK1 (0.73) | CLK1CDK5CDK5R1MAP3K14PDK1 | |
| SCHEMBL16205545 | 0.79 | CLK1 (0.43) | CLK1CDK5CDK5R1MAP3K14 | |
| SCHEMBL16205606 | 0.79 | CLK1 (0.43) | CLK1CDK5CDK5R1MAP3K14 | |
| SCHEMBL20691183 | 0.77 | CLK1 (0.71) | CLK1CDK5CDK5R1MAP3K14GSK3B | |
| SCHEMBL21096557 | 0.76 | CLK1 (0.46) | CLK1CDK5CDK5R1MAP3K14PDK1 | |
| SCHEMBL16205623 | 0.76 | CLK1 (0.41) | CLK1CDK5CDK5R1MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209662-B1 | NEW COMPOUNDS AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| US-10005776-B2 | Compounds as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-26 | — | — | US | disclosed |
| US-20170334906-A1 | NEW COMPOUNDS AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| WO-2014174021-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005776-B2 | Compounds as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | CLK1 222/4885CDK5 1006/4885CDK5R1 1075/4885 |
| US-20170334906-A1 | NEW COMPOUNDS AS NIK INHIBITORS | MAP3K14, IKBKG, MAP3K15 | CLK1 255/4885CDK5 962/4885CDK5R1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.